Tequin and Ipratropium bromide drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Tequin (gatifloxacin) and Ipratropium bromide (ipratropium bromide). Common drug interactions include bone disorder among females and hyperglycaemia among males.

The phase IV clinical study analyzes what interactions people have when they take Tequin and Ipratropium bromide. It is created by eHealthMe based on reports of 35 people who take the same drugs from the FDA, and is updated regularly.

What is Tequin?

Tequin has active ingredients of gatifloxacin. eHealthMe is studying from 4,645 Tequin users. Check the latest studies of Tequin.

What is Ipratropium bromide?

Ipratropium bromide has active ingredients of ipratropium bromide. It is often used in chronic obstructive pulmonary disease. eHealthMe is studying from 17,965 Ipratropium bromide users. Check the latest studies of Ipratropium bromide.



On Jul, 14, 2026

35 people who take Tequin and Ipratropium bromide together, and have interactions are studied.

Tequin and Ipratropium bromide drug interactions.

What are the common drug interactions of Tequin and Ipratropium Bromide, by gender? *:

female:

  1. Bone disorder
  2. Bone marrow failure
  3. Cardiac failure congestive
  4. Dental caries
  5. Diabetes mellitus (diabetes, caused by a deficiency of the pancreatic hormone insulin)
  6. Dysphonia (speech disorder attributable to a disorder of phonation)
  7. Facial pain
  8. Groin pain
  9. Intervertebral disc disorder (spinal disc disorder)
  10. Joint effusion (presence of extra fluid in joint covering)

male:

  1. Hyperglycaemia (high blood sugar)
  2. Hypoglycaemia (deficiency of glucose in the bloodstream)
  3. Abdominal discomfort
  4. Abdominal distension
  5. Abdominal pain upper
  6. Abdominal tenderness
  7. Abscess (pus)
  8. Acute prerenal failure (prerenal acute renal failure (arf) occurs when a sudden reduction in blood flow to the kidney)
  9. Anxiety
  10. Apnoea (suspension of external breathing)

What are the common drug interactions of Tequin and Ipratropium Bromide, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

n/a

40-49:

  1. Cardiomyopathy (weakening of the heart muscle)
  2. Cough
  3. Cytomegalovirus infection
  4. Dyspnoea (difficult or laboured respiration)
  5. Ejection fraction (the percentage of blood that is pumped out of a filled ventricle as a result of a heartbeat)
  6. Forced expiratory volume decreased (decreased lung expired air volume)
  7. Hyperglycaemia (high blood sugar)
  8. Lung infiltration (a substance that normally includes fluid, inflammatory exudates or cells that fill a region of lung)
  9. Night sweats (sweating in night)
  10. Oxygen saturation decreased

50-59:

  1. Hypertensive cardiomyopathy (heart disease caused by high blood pressure)
  2. Hypoglycaemia (deficiency of glucose in the bloodstream)
  3. Lethargy (tiredness)
  4. Loss of consciousness
  5. Nausea (feeling of having an urge to vomit)
  6. Nervous system disorder (a general class of medical conditions affecting the nervous system)
  7. Pulmonary oedema (fluid accumulation in the lungs)
  8. Pyrexia (fever)
  9. Renal failure chronic (long lasting kidney dysfunction)
  10. Respiratory failure (inadequate gas exchange by the respiratory system)

60+:

  1. Anxiety
  2. Renal failure (kidney dysfunction)
  3. Dysphonia (speech disorder attributable to a disorder of phonation)
  4. Facial pain
  5. Fall
  6. Groin pain
  7. Hypoglycaemia (deficiency of glucose in the bloodstream)
  8. Injury
  9. Intervertebral disc disorder (spinal disc disorder)
  10. Joint effusion (presence of extra fluid in joint covering)

What are the existing conditions these people have? *

  1. Pain: 11 people, 31.43%
  2. Muscle Spasms (muscle contraction): 8 people, 22.86%
  3. Pneumonia: 4 people, 11.43%
  4. Stress And Anxiety: 3 people, 8.57%
  5. Depression: 3 people, 8.57%
  6. High Blood Cholesterol: 3 people, 8.57%
  7. Joint Pain: 3 people, 8.57%
  8. Infection: 3 people, 8.57%
  9. Nasal Congestion (blockage of the nasal passages usually due to membranes lining the nose becoming swollen from inflamed blood vessels): 2 people, 5.71%
  10. Gastroesophageal Reflux Disease (a condition in which stomach contents leak backward from the stomach into the oesophagus): 2 people, 5.71%

* Approximation only. Some reports may have incomplete information.

Do you take Tequin and Ipratropium bromide?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously



Related studies:

Effectiveness of, side effects of, and alternative drugs to the 2 drugs:

Browse all drug interactions of Tequin and Ipratropium bromide:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Tequin:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all side effects of Ipratropium bromide:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Tequin and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Ipratropium bromide and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

How the study uses the data?

The study uses data from the FDA. It is based on gatifloxacin and ipratropium bromide (the active ingredients of Tequin and Ipratropium bromide, respectively), and Tequin and Ipratropium bromide (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.



Recent studies on eHealthMe: